Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia

The poor prognosis for elderly patients with acute myeloid leukemia (AML) raises questions regarding the benefit of treating them with intensive chemotherapy. The impact of initial characteristics on prognosis has been addressed previously in elderly patients; however, very few data are available regarding the prognostic value of immunophenotypic characteristics in this setting.

[1]  S. Tura,et al.  The presence of lymphoid‐associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance , 1995, Stem cells.

[2]  Yi Ning,et al.  Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. , 2006, Blood.

[3]  J. Bourhis,et al.  Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. , 2007, Blood.

[4]  P. Sonneveld,et al.  Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Fröhling,et al.  Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. , 2006, Blood.

[6]  Susan O'Brien,et al.  Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: , 2006, Cancer.

[7]  Y C Chen,et al.  Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. , 1995, Cancer genetics and cytogenetics.

[8]  R. Willemze,et al.  Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia , 1999, Leukemia.

[9]  M. Vignetti,et al.  Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. , 2005, Blood.

[10]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[11]  A. Delmer,et al.  Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period , 1999, Leukemia.

[12]  J. Rowe.  Treatment of acute myelogenous leukemia in older adults , 2000, Leukemia.

[13]  J. Yin,et al.  Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival , 1993, British journal of haematology.

[14]  D. Treille,et al.  Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy , 1989, British journal of haematology.

[15]  R. Zapf,et al.  Primitive AML progenitors from most CD34(+) patients lack CD33 expression but progenitors from many CD34(-) AML patients express CD33. , 2007, Cytotherapy.

[16]  E. Solary,et al.  Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucémies (GEIL). , 1992, Leukemia.

[17]  A. Órfão,et al.  Prognostic value of immunological markers in acute myeloblastic leukemia. , 1989, Leukemia.

[18]  N. Casadevall,et al.  The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. , 2000, Blood.

[19]  M. Minden,et al.  Disease biology rather than age is the most important determinant of survival of patients ≥ 60 years with acute myeloid leukemia treated with uniform intensive therapy , 2005, Cancer.

[20]  D. Grimwade,et al.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[21]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[22]  A. Hagenbeek,et al.  Detection of Minimal Residual Disease in Acute Leukemia by Flow Cytometry a , 1986, Annals of the New York Academy of Sciences.

[23]  C. Bloomfield,et al.  Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. , 1986, Blood.

[24]  C. Marosi,et al.  Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Vignetti,et al.  Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. , 2007, Haematologica.

[26]  J. Matthews,et al.  Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. , 1994, Blood.

[27]  A. Wåhlin,et al.  Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia , 2001, British journal of haematology.

[28]  E. Estey.  How I treat older patients with AML. , 2000, Blood.

[29]  M. Minden,et al.  Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. , 2004, Leukemia research.

[30]  T. Lister,et al.  Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome , 1990, Hematological oncology.

[31]  S. Piantadosi,et al.  Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem‐cell glycoprotein CD34 (My 10) , 1990, British journal of haematology.

[32]  J. S. Stevenson,et al.  Older Adults , 1980, Suicide Prevention.

[33]  J. Szer,et al.  The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis? , 2006, Blood reviews.

[34]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[35]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.